

CONSENT FORM

TITLE: A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Ertapenem Sodium (MK-0826) Versus Cefotetan for the Prophylaxis of Surgical Site Infection Following Elective Colorectal Surgery

PROTOCOL No.: 039-01

You are invited to be in a research study. You need to decide whether you want to participate or not. Please take your time to make your decision. Carefully read the following and ask the study doctor any questions which you may have. The study is being conducted for Merck & Co., Inc.

Why is this study being done?

The purpose of this study is to test the safety of the research study drug INVANZ™ (ertapenem sodium). Another purpose is to see if INVANZ™ has an effect on preventing surgical site infection following elective colorectal surgery.

Who should not be in the study?

You should not be in the study if any of the following statements apply to you. The study doctor or his/her staff can help explain these statements and discuss them with you:

- You are less than 18 years of age.
- You are undergoing emergency colorectal surgery (unscheduled surgery with not enough time to complete the bowel preparation before surgery).
- You require a second planned colorectal surgery or other surgery requiring antibiotic preventative treatment within the 4-week follow-up period.
- You are undergoing a surgery that will use a laparoscope (a special instrument used by the surgeon to conduct the procedure).
- You are undergoing an isolated rectal procedure.
- You have a certain type of blockage in your intestines.
- You have active inflammatory bowel disease involving the colon.
- You are scheduled to undergo a certain type of elective colorectal procedure for revision of a previous operation involving the large bowel.

- You have a bacterial infection at the time of surgery or you have a need to receive antibiotic therapy within 1 week before your surgery.
- You require antibiotic therapy to prevent certain other types of infections and/or you have another condition at the beginning of the study that requires antibiotic therapy during the course of the study.
- You have a history of serious allergy, hypersensitivity, or any serious reaction to either of the study drugs or related drugs.
- You are pregnant, nursing, or a woman of childbearing potential not practicing adequate methods of birth control; or you are planning to become pregnant within 1 month of the study.

Note: Females of childbearing potential must have a negative blood pregnancy test prior to enrolling in the study and must use adequate birth control measures as discussed with the investigator for at least 1 month after study treatment. Your study doctor can discuss methods of birth control with you and refer you elsewhere for more information, if needed.

- You have laboratory results that would prevent you from participating.
- You have a weak immune system caused by one of several factors.
- You have a history of any illness or require treatment that, in the opinion of the investigator, might confuse the results of the study or cause the possibility of additional risk in giving you the study drug.
- You have participated in any other clinical study involving taking study medication in the 30 days before enrolling in the study, or you have previously participated in this study at any time.
- You or a legal representative are unable to provide written informed consent for any reason.

There may be other reasons why you cannot participate which will be discussed with you by the study doctor or his/her staff.

What will I be asked to do? What are my requirements?

The study doctor or his/her staff will ask you about your medical history and will examine you. You will be required to visit the study doctor about 3 times in addition to your hospital stay. During the study you will be assigned to either receive one dose of ertapenem or one dose of cefotetan by intravenous (medicine will be slowly dripped through a tube into your vein by way of a needle) just prior to your planned colorectal surgery. You have a 1 in 2 chance (like the flip of a coin) of receiving the study drug (ertapenem). You and your study doctor will not know whether you are receiving

ertapenem or cefotetan. In an emergency, information about what drug you are on can be obtained quickly.

Before you receive the study medication, the study doctor or his/her staff will do the following:

- Discuss your medical history;
- Perform a physical examination and measure your vital signs;
- Obtain a blood sample (about 1 tablespoon) from your arm to test your blood count, blood clotting function, and liver and kidney function (this will be done twice before your surgery). A blood pregnancy test will be done for women of childbearing potential;
- Collect a urine sample for testing.

Before surgery you will undergo a routine bowel preparation to empty and cleanse the bowel. Your study doctor or his/her staff will instruct you in the proper procedure and timing for taking this preparation. About one hour before surgery you will be given study drug intravenously.

After your surgery, the following will happen:

- Your vital signs will be measured daily by the study doctor or his/her staff;
- You will be examined by the study doctor or his/her staff at least every other day for the first week or until the day you are discharged from the hospital (whichever comes first);
- You will receive a telephone call approximately 14 days after the surgery to monitor for adverse events;
- You will be required to visit the study doctor one time, approximately 4 weeks after you have been discharged from the hospital.

At your visits (during the time you are in the hospital and after you have been discharged from the hospital) the study doctor or his/her staff may do any or all of the following:

- Perform physical examination and measure your vital signs;
- Perform specific abdominal and wound examinations to look for signs of infection;
- Obtain bacterial cultures if you develop symptoms or signs of infection;
- Obtain a blood sample from your arm (about 1 tablespoon) for blood cultures if you develop symptoms or signs of infection.

What is known about this study drug?

The drug INVANZ™ has been used in about 2000 subjects.

How long will I be in the study?

You will be in the study about 8 weeks.

How many other people will be participating in the study?

About 900 people will be participating in the study.

Will I be paid?

You will be paid as follows:

(insert payment information here. Must be pro rated.)

What adverse (bad) effects can happen to me by participating in the study?

The following adverse (bad) effects have been reported by people taking ertapenem in previous studies or seen in animal experiments. The most common adverse effects related to ertapenem are:

- Headache
- Diarrhea, nausea, vomiting
- Vaginitis
- Infusion related complications (problems with the vein into which the medicine is given including inflammation and irritation of the vein)
- Alterations in some laboratory blood tests (increased platelet counts, increased eosinophils, elevated liver function blood tests and decreased white blood cells)

There have been other reported adverse effects such as:

- Rash, skin redness, itching
- Dizziness, sleeplessness, anxiety, altered mental status, seizure
- Low blood pressure, increased heart rate, leaking of fluid into the tissue and skin around the injection site, high blood pressure
- Shortness of breath, yeast infection of the mouth, constipation, acid regurgitation, indigestion
- Abdominal pain, fatigue, swelling, fever, chest pain, death (all deaths were considered unrelated to the study drug, and generally occurred in patients with severe infection and/or pre-existing diseases)
- Leg pain
- Cough, sore throat, abnormal breathing sounds, respiratory distress

The adverse (bad) effects of cefotetan (or other drugs similar to cefotetan, the cephalosporin antibiotics) may include the following:

- Diarrhea, nausea, vomiting, abdominal pain, rash, itching, fever, seizure, as well as local reactions at the infusion site (inflammation and irritation of the vein or pain at the injection site)
- There have been changes in blood cell counts, and there have been cases of elevated liver and kidney function blood tests, anemia as well as decreased white blood cells and platelets

Since the effect of ertapenem on hormonal contraceptives has not yet been established, if you are using oral contraception as a method of birth control, you should use another method (i.e. condom, spermicide) at the same time while on this study and for at least one month afterwards.

Serious and occasionally fatal severe allergic reactions have been reported in patients on antibiotic therapy. You will be monitored for any possible reactions while receiving your antibiotic therapy.

You may experience pain, numbness, bruising, swelling or rash at the site of injection, and rarely infection. Fainting has also been reported.

There are other less common adverse effects which your study doctor can identify for you. The study doctor or staff will discuss these with you. There can be other adverse effects that are not presently known about the study drugs. It is not known how the study drug(s) may affect an unborn baby.

If I have an adverse effect, who will pay the doctor and hospital bills?

If you are injured or become sick directly from the Merck study drug, Merck & Co., Inc. will pay for the reasonable costs of medical treatment except for costs that are covered by your medical insurance, hospital insurance, third-party payors, or governmental programs. No other form of compensation is available.

What benefit can I expect?

If the drug works, you may have some benefit. On the other hand, it may not work and there may be no benefit.

Are there any other drugs that I may be able to take or things that I can do for my condition/disease, if I don't want to participate in the study?

There are a number of approved antibiotics, such as cefotetan, which can be used to prevent post-operative infection at the surgical site. Your study doctor will discuss these options with you.

Who will be able to see my records and know that I am in the study?

If you agree to become part of this study, your name will be held in confidence. Unless required by law, only the study doctor and staff, sponsor representatives involved in this study, independent ethics committees and inspectors from government regulatory agencies will have direct access to your medical records to check the study information.

Will I be told if new information about the drug is discovered during the study?

You will be told in a timely manner of any significant new information that may affect your willingness to stay in this study.

Who do I call if I have questions?

For questions about your rights as a study subject, call [insert name] at [insert area code and telephone number].

For questions about the study, call the study doctor [insert name] at [insert area code and telephone number].

If you have a study-related injury, call [insert name] at [insert area code and telephone number].

Can I refuse to be in the study and can I be asked to leave the study?

Your participation in this study is voluntary. You can choose not to take part in the study, or you can quit at any time. You will not lose any benefits to which you are otherwise entitled. If you quit the study, you can receive the standard treatment for this condition. You will not be prevented from participating in future studies. This research is funded by a grant from Merck & Co., Inc. to the Institution to conduct this study.

You may be asked to leave the study by the study doctor or Merck & Co., Inc. without your consent if you need other treatment, if you do not follow the study plan, if you have a study-related injury, or for any other reason. If you leave the study, the doctor may ask to examine you and do some final tests.

You will receive a signed copy of this consent form.

I have read and understand this consent form. All my questions have been answered. I volunteer to take part in this study.

Signature of Volunteer

Date

Signature of Person Conducting Review of Consent

Date